We previously reported that follistatin-related protein (FRP)/TSC-36 was one of the target antigens of autoantibodies in rheumatoid arthritis (RA) and that the appearance of serum autoantibodies to FRP correlated to disease activity in RA. However, the signi®cance of FRP in autoimmunity remained to be explained due to the unknown function of FRP. Here, we disclose in part the function of FRP. Transforming growth factor (TGF)-b augmented FRP gene expression in synovial cells. FRP reduced synovial production of matrix metalloproteinase (MMP)-1, MMP-3 and prostaglandin E 2 , potent agonists of joint destruction in RA. In contrast, autoantibodies to FRP from patients with RA increased their production by blocking FRP activity, probably in the autocrine system. Moreover, FRP down-regulated synovial expression of FOS (c-fos), which seemed responsible for the reduction in MMP-1 and MMP-3 caused by FRP. Therefore, FRP and its autoantibody can be regarded as defensive and offensive factors respectively in rheumatoid arthropathy. The major epitope of autoantibodies to FRP was mapped to the sequence LKFVEQNE (residues 169±176) and homologous sequences were found in proteins from Escherichia coli, Epstein±Barr virus, etc. FRP and its autoantibody may provide some clues to elucidate the process of disease development and a new approach to the design of therapeutics in RA.
Introduction
Follistatin-related protein (FRP) was discovered as the product of the transforming growth factor (TGF)-b1-inducible gene, TSC-36, in a murine osteoblastic cell line, MC3T3-E1 (1) . FRP was named after follistatin, an inhibitor of activin, for having an amino acid sequence similar to a characteristic structure unit in follistatin, called the follistatin (FS) domain (2) . The chick counterpart gene and protein of FRP are known as the follistatin-like (Flik) gene and protein (3) . FRP is a secreted protein with a mol. wt of 50±55 kDa and is expressed in all organs except peripheral blood leukocytes. Human FRP is registered in the databases of Online Mendelian Inheritance in Man (OMIM; Johns Hopkins University, http://www3.ncbi.nlm.nih.gov/omim), and its entry name is FOLLISTATIN-LIKE 1 (FSTL1). There is another reported FS domain-bearing protein encoded by the gene named follistatin-related gene (FLRG), registered as FOLLISTATIN-LIKE 3 (FSTL3) in OMIM, which was overexpressed in a B cell leukemia (4) . Recently, to our confusion, the product of FLRG has also been called`follistatin-related protein (FSRP)' (5). It is not FRP but FSRP that has been demonstrated to have activinbinding activity (6) . It is still unknown which molecules associate with FRP. FRP is an orphan molecule. Although the physiological function of FRP remains to be clari®ed, it is being partially disclosed. In human lung cancer cells, FRP had negative regulatory effects on growth (7) . In development, a reduction in FRP gene expression brought about de®cient axial patterning and holoprosencephaly, suggesting a modulating effect on signaling through bone morphogenetic protein or TGF-b-related ligands (8) .
We cloned FRP as an autoantigen in rheumatoid arthritis (RA) and other systemic autoimmune diseases, and disclosed that the appearance of serum autoantibodies to FRP was predominant in RA (30%) and correlated with disease activity in patients with RA (9) . However, we could not explain the signi®cance of the production of autoantibodies against FRP in RA because of lack of information about the physiological role of FRP. TGF-b is the key to a breakthrough here, because as an inducer of FRP it is the only molecule known at present that has a functional association with FRP.
The de®nite pathophysiological role of TGF-b in RA has not been settled as yet. On one hand, TGF-b is thought to have protective effects on destructive arthritis in RA by antagonizing pro-in¯ammatory cytokines such as IL-1, tumor necrosis factor (TNF)-a and platelet-derived growth factor, which induce in¯ammation, enzyme release, synovial cell proliferation and destruction of joint structure (10±14). On the other hand, TGFb is thought to have synergistic effects on arthritis with the proin¯ammatory cytokines and to recruit leukocytes to synovial tissues resulting in synovial hyperplasia (15±17). This contradiction may originate from experiments using different culture conditions or animal models.
In arthropathy of RA, matrix metalloproteinases (MMP) have a direct effect on joint destruction (18) . MMP-1 (interstitial collagenase) and MMP-3 (stromelysin-1), in particular, are thought to play a major role, because MMP-1 is the only enzyme capable of ef®ciently degrading interstitial collagens by cleaving their triple helical domains, and MMP-3 has a wide spectrum of substrates including non-collagenous proteins, gelatin and laminin (19) . It is reported that TGF-b suppresses synovial production of MMP and may take part in the prevention of extracellular matrix degradation (20, 21) . Prostaglandin E 2 (PGE 2 ) is another factor responsible for the destruction of rheumatoid joints and the most potent stimulator of bone resorption among the prostaglandins (21) .
The pivotal role of TGF-b in rheumatoid arthropathy led us to speculate that FRP would have agonistic or antagonistic functions for or against TGF-b in the disease process. Therefore, we investigated the functions of FRP by estimating the effect it and its antibody has on synovial expression of MMP-1, MMP-3 and PGE 2 , and moreover the effects of FRP on FOS (c-fos) (22) , a candidate for the gene responsible for the tumor-like growth of synovium (23) . Based on the results of those experiments, we attempted to elucidate the pathophysiological signi®cance of autoimmunity to FRP in RA.
Methods

Preparation of recombinant FRP
We produced two types of recombinant human FRP. Escherichia coli-expressed FRP, GST±FRP, was prepared as previously described (9) . The GST tag was removed from GST±FRP and the protein was puri®ed by a perfusion chromatography method with a POROS HE column (Applied Biosystems, Foster City, CA). Since it was easy to prepare a large quantity of E. coli-expressed FRP, we used this type mainly in Northern blotting analyses. On the other hand, COS-7-expressed FRP, FLAG±FRP, was created as Pati and Chubet described (24, 25) . A DNA cassette with 5¢ SalI and 3¢ SmaI ends encoding preprotrypsinogen signal peptide and FLAG epitope tag sequentially was produced by annealing synthetic complementary oligonucleotides (sense: 5¢-TC GAC ACC ATG TCT GCA CTT CTG ATC CTA GCT CTT GTT GGA GCT GCA GTT GCT GAC TAC AAA GAC GAT GAC GAC AAA GGA TCC C-3¢; anti-sense: 5¢-G GGA TCC TTT GTC GTC ATC GTC TTT GTA GTC AGC AAC TGC AGC TCC AAC AAG AGC TAG GAT CAG AAG TGC AGA CAT GGT G-3¢). This DNA cassette was cloned in a SalI + SmaI-digested pSL1180 vector (Amersham Pharmacia Biotech, Uppsala, Sweden), and ligated with signal sequence-minus FRP cDNA bearing 5¢ SmaI and 3¢ XhoI ends in the vector (9) . The resultant FLAG± FRP cDNA was isolated by digestion with SalI and XhoI, ligated into mammalian expression vector pCXN2 at the XhoI site, and transfected into COS-7 cells. pCXN2 vector was kindly provided by J. Miyazaki (Department of Nutrition, Osaka University, Osaka, Japan). FLAG±FRP in culture medium was puri®ed with an Anti-FLAG M2 af®nity gel (Eastman Kodak, New Haven, CT) according to the manufacturer's protocol.
Antibodies
Mouse mAb to human FRP (ANOC9703) was produced with GST±FRP by standard methods. F(ab¢) 2 fragments of ANOC9703 mAb were prepared with an ImmunoPure F(ab¢) 2 preparation kit (Pierce, Rockford, IL). Af®nity-puri®ed autoantibodies to FRP were derived from three patients with RA (RA21, RA22 and RA23). They were puri®ed with a HiTrap Protein G column (Amersham Pharmacia Biotech) and an FRP-af®nity column. The FRP-af®nity column was prepared by coupling GST tag-removed GST±FRP with NHS-activated Sepharose-4B (Amersham Pharmacia Biotech). The deduced percentages of puri®ed autoantibodies to FRP in serum total IgG from RA21, RA22 and RA23 were 0.21, 0.14 and 0.25 respectively. Mouse control IgG was purchased from Serotec (polyclonal mouse IgG, PMP01; Oxford, UK). Human control IgG was puri®ed from a pooled serum mixture of six normal healthy subjects with the HiTrap Protein G column.
Analysis of MMP-1 and MMP-3 production in synovial cells
Cells (3 Q 10 3 ) of the human synovial cell line SF-1 (26) or cells (5 Q 10 3 ) of the rabbit synovial cell line HIG-82 (CRL-1832; ATCC, Rockville, MD) were inoculated into the wells of 96-well plates ®lled with 200 ml of RPMI 1640 or F12 in triplicate respectively. They were cultured in medium with 10% FCS for 72 h. After the medium was exchanged for fresh medium without FCS but with rFRP and/or antibodies, or fresh medium with 0.1% FCS, which is necessary for cytokine response, and rFRP plus an aliquot of cytokine, they were cultured for the next 72 h. The cytokines used were IL-1b (Strathmann Biotech, Hannover, Germany), TNF-a (PeproTech, London, UK), IL-6 and soluble IL-6 receptor in pairs (R & D Systems, Minneapolis, MN), and oncostatin M (PeproTech). Thereafter the culture supernatant was collected and the cells were enumerated. Activities of MMP-1 and MMP-3 in 50 ml aliquots of the culture supernatant were assayed with commercially available kits (YU-16001 and YU-26001; Yagai, Yamagata, Japan). MMP in the samples were activated by p-aminophenylmercuric acid (A-9563; Sigma, St Louis, MO) according to the manufacturer's protocol. The¯uorescence of the reactants was measured with a FluorImager and its software ImageQuaNT (Molecular Dynamics, Tokyo, Japan).
Evaluation of PGE 2 production in synovial cells
Concentrations of PGE 2 in the culture supernatant were measured with a Correlate-EIA PGE 2 enzyme immunoassay kit (Assay Designs, Ann Arbor, MI).
Northern blotting studies of synovial cells SF-1 cells were cultured in an FCS-free medium with 0.1% BSA for 72 h and then stimulated with 2 ng/ml of TGF-b1 (Genzyme, Cambridge, MA) or 300 ng/ml of rFRP in fresh FCS-free 0.1% BSA medium. After the stimulation, RNA was isolated from cells with TRIzol reagent (Gibco/BRL, Gaithersburg, MD). The probe for FRP was described previously (9) . The probes for MMP-1 and MMP-3 were cloned from RT-PCR products of SF-1 RNA with an Original TA cloning kit (Invitrogen, Carlsbad, CA). The 5¢ and 3¢ primers for MMP-1 were 5¢-TGG ATC CAG GTT ATC CCA AA-3¢ and 5¢-GGT GAC ACC AGT GAC TGC AC-3¢ respectively. Those for MMP-3 were 5¢-TCA GAA CCT TTC CTG GCA TC-3¢ and 5¢-GCT GAC AGC ATC AAA GGA CA-3¢ respectively. The annealing temperature for both the primer sets was 62°C. The probe for FOS was prepared from human FOS cDNA (27) (CO054; Health Science Research Resources Bank, Osaka, Japan). Signal densities were measured by Image software (Scion, Frederick, MD).
Fine epitope mapping
Generally, ®ne epitope mapping is performed with a set of overlapping peptides designed to scan 10-to 15-amino-acid sequences of the protein by residues from the N-to Cterminus. To investigate T cell epitopes of the FRP molecule, however, we prepared peptide fragments of FRP including potential binding motifs for DRB1*0401 (DR4), DRB1*0405 (DR4) and DQ4 molecules, which V. Brusic kindly designed by computer analysis (28, 29) . We successfully applied these peptides to epitope mapping (B cell epitope mapping) of the FRP molecule. Methods of peptide synthesis and ELISA with antigen peptide were described previously (26) .
Homology search of proteins
Homologous protein sequences were found using the FASTA program on the GenomeNet service (http://www.genome.ad.jp).
Results
The effect of FRP and its autoantibody on synovial cells
To investigate the effects of FRP and its antibody on rheumatoid arthropathy, we treated synovial cells with rFRP, its mAb or autoantibodies from patients with RA. Indeed, for the purpose of these studies, synovial cells should be fresh from synovial tissue, but it was dif®cult to prepare such cells abundantly and to get ®xed conditions in a different series of studies. Thus, we used synovial cell lines. rFRP suppressed MMP-1, MMP-3 and PGE 2 production in the human and rabbit synovial cell lines SF-1 and HIG-82 in a dose-dependent manner (Fig. 1A) . In contrast, mAb to human FRP, ANOC9703, increased MMP-1 and MMP-3 production in SF-1 cells in a dose-dependent manner (Fig. 1B) : PGE 2 could not be estimated because mouse mAb to human FRP in the sample medium prevented mouse mAb to PGE 2 from reacting with plate-coated anti-mouse IgG antibodies in this ELISA system. Similarly, autoantibodies to FRP from patients with RA raised MMP-1, MMP-3 and PGE 2 production in a dose-dependent manner in both SF-1 and HIG-82 (Fig. 2) . To con®rm that the inhibitory effect of rFRP was indeed mediated by rFRP, but not contaminants, we examined whether the preincubation of rFRP with anti-FRP mAb can abolish the observed inhibitory effect. Anti-FRP mAb diminished the inhibitory effect by neutralizing rFRP activity in a dose-dependent manner (Fig. 3A) . Thus, rFRP exerted a signi®cant inhibitory effect on synovial cells. In addition, rFRP inhibited the induced production of MMP-1 from synovial cells activated by IL-1b, TNF-a, IL-6 and oncostatin M (Fig. 3B) . Next, to exclude the possibility that the promotion of synovial MMP and PGE 2 production by antibodies to FRP was due to the Fcg receptor-mediated activation of synovial cells following FRP±anti-FRP immune complex formation, we treated synovial cells with anti-FRP mAb F(ab¢) 2 lacking the Fc portion. Anti-FRP mAb F(ab¢) 2 also increased MMP-1 production in SF-1 cells in a dose-dependent manner (Fig. 3A) . Northern blotting analysis showed that FRP was intrinsically expressed in non-treated synovial cells (lane 0 h of Fig. 4A ). Therefore, antibodies to FRP seemed to neutralize endogenous FRP activity probably in the autocrine system to exert a reversing effect. Down-regulation of MMP-1 and MMP-3 by rFRP was observed also at the mRNA level (Fig. 4B) . FOS is an immediate early gene whose expression is regulated rapidly (30) . rFRP also down-regulated FOS expression in 60 min (Fig. 4B) . This suggested that the suppressive effects on MMP-1 and MMP-3 of FRP originated from its negative regulation of FOS. In this series of experiments, we did not observe any apparent growth inhibition of SF-1 cells by rFRP (data not shown).
FRP gene regulation by TGF-b in synovial cells
FRP was originally cloned as a TGF-b1-inducible protein in the murine osteoblastic cell line MC3T3-E1 (1). Thus, we studied the regulation of the FRP gene by TGF-b in synovial cells. As in MC3T3-E1 cells, TGF-b1 up-regulated the expression (Fig. 4A) .
Epitope mapping of FRP recognized by autoantibodies in RA
We previously found the autoantigenic epitope of FRP to be located in the EC domain between the FS domain and the EFhand by a crude epitope mapping method (9) . To clarify this epitope further, we performed ELISA with the 14±24mer peptide fragments of FRP described in Methods. The results are shown in Fig. 5 . All of the autoantibodies from three representative patients with RA reacted to the peptide with the sequence FDNGDSRLDSSEFLKFVEQNE (no. 10 peptide). However, they reacted only slightly to the peptide with the sequence YFKNFDNGDSRLDSSEF (no. 9 peptide), part of which was included in the no. 10 peptide. Thus, we concluded that the sequence LKFVEQNE (residues 169±176), a part of no. 10 peptide not shared by no. 9 peptide, composed the epitope of FRP. This result supports that of crude epitope mapping (9) . Interestingly, the sequence LKFVEQNE was included in another predictive DRB1*0401-binding motif LKFVEQNET (residues 169±177), which was also designed by V. Brusic as described in Methods, but was too short to use in the peptide ELISA. The signi®cance of this potential coincidence is unknown, although a similar coincidence has been demonstrated in other protein antigens (31, 32) . The T cell response to the FRP molecule and T cell epitope mapping are under investigation.
Homology search of the epitope sequence
Amino acid sequences homologous to the LKFVEQNE epitope were found in proteins from infectious microbes; ±±FVEQNE in rFRP inhibited the induced production of MMP-1 from synovial cells activated by IL-1b (10 ng/ml), TNF-a (10 ng/ml), IL-6 plus soluble IL-6 receptor (100 and 10 ng/ml) and oncostatin M (10 ng/ml), as shown in graphs IL-1, TNF, IL-6 and OM, respectively (P < 0.0005, IL-1; P < 0.005, OM; P < 0.01, IL-6, tested among rFRP-treated sample values by one-factor ANOVA). C: control culture without cytokine or rFRP. Fig. 2 . Enhancement of MMP-1, MMP-3 and PGE 2 production by af®nity-puri®ed autoantibodies to FRP in RA. Af®nity-puri®ed anti-FRP autoantibodies from patients with RA increased MMP-1, MMP-3 and PGE 2 production both in SF-1 and HIG-82 cells, probably due to their inactivation of autocrine FRP (P < 0.005: RA21, RA22 and RA23 in graphs 1, 2 and 5, RA21 and RA22 in graph 4; P < 0.05: RA22 and RA23 in graph 3, and RA21 in graph 6; compared to controls by two-factor factorial ANOVA).
E. coli 4-hydroxybenzoate synthetase (S25660), LKFVE±N± in Rickettsia prowazekii 3-deoxy-d-manno-octulosonic-acid transferase RP089 (H71717), ±KFVE±NE in Epstein±Barr virus DNA-directed DNA polymerase (DJBE2L), etc. (PIR accession numbers in parentheses).
Discussion
We previously reported that FRP is an autoantigen whose autoantibodies appear in association with disease activity in RA (9) . FRP is a secreted protein with a similar structure to follistatin, an inhibitor of activin (2) . Its function, however, remained to be clari®ed. Here, we disclosed part of its function. FRP suppresses MMP-1, MMP-3 and PGE 2 production in synovial cells, and autoantibody to FRP from patients with RA increases their synovial production by blocking FRP activity, probably in the autocrine system. This result suggests that, in vivo, FRP may be a synovial defensive factor together with protease inhibitors such as tissue inhibitor of MMP (33) and that the autoantibody to FRP may be an offensive factor for articular matrix degradation. TGF-b up-regulates synovial expression of FRP. Therefore, it is possible that the reported anti-arthritic effect of TGF-b may be mediated in part by the functions of FRP.
In these experiments, we used synovial cell lines derived from spontaneous transformants, SF-1 and HIG-82, in order to ensure the reproducibility of assays and to perform many experiments ef®ciently. Since cells in synovial tissue are quite heterogeneous, test results could differ depending on the source and culture period. HIG-82, a rabbit cell line, was also used because it was well studied and thought to stand for synovial tissue cells (34±36). We found that SF-1 preserved the features of cytokine responses among synovial cells as well as HIG-82 cells (data not shown). However, these in vitro studies cannot conclude the functions of FRP in cytokine-rich rheumatoid joint milieus. We are now investigating FRP effects on arthritis in vivo by using animal models.
FRP down-regulates the expression of FOS in synovial cells. FOS is transcribed in rheumatoid synovial cells and thought to be one of the genes responsible for the tumor-like phenotypes of synovium in RA (23) . FOS (c-Fos), the protein encoded by FOS, forms a heterodimer complex, activation protein (AP), with JUN and related proteins, and acts as a transcription factor by binding to speci®c DNA sequences, AP-1 sites (37). Many of the promoter DNA sequences for MMP including MMP-1 and MMP-3 contain AP-1 sites, and the AP-1-forming proteins, especially FOS, regulate their transcriptional control (38) . Therefore, the reduction in the expression of MMP-1 and MMP-3 caused by FRP may originate from the down-regulation of FOS.
In terms of the actual pathophysiological role of FRP in RA, its negative regulation of MMP-3 seems to have more importance than that of MMP-1. The serum concentration of MMP-3 is not only signi®cantly correlated with disease activity indices such as C-reactive protein and IL-6 levels, but also a promising marker for predicting bone damage in the early stage of RA (39, 40) . Suppression of PGE 2 production by FRP is also a notable phenomenon. PGE 2 is the most potent stimulator of bone resorption among the prostaglandins (21) . In addition, PGE 2 is associated with collagenase production in rheumatoid synovial cells (41) . Therefore, the down-regulation of MMP-3 and PGE 2 by FRP suggests that FRP plays no small part in the prevention of rheumatoid arthropathy, and that the neutralizing autoantibody to FRP is a potential promoter of joint destruction.
We previously reported that a considerable number of patients with RA had autoantibodies to a soluble form of the IL-6 signal transducer gp130, named gp130-RAPS, and that gp130-RAPS inhibited IL-6 activity and autoantibodies to gp130-RAPS neutralized such inhibition (26) . Autoantibodies to calpastatin, an inhibitor of calpain, were also reported in the sera of some patients with RA (42, 43) and to neutralize calpastatin activity in vitro (42) . Calpain can degrade the matrix components of articular cartilage as well as nuclear proteins, cytokines and structural proteins (44) . Menard et al. proposed that autoantibodies to calpastatin have promoting effects on the progression of RA (44) . Therefore, antagonistic autoantibodies to potential negative regulators of disease progression, including FRP, may play a role through the modulation of disease development in RA. To our surprise, it was reported that neutralizing autoantibodies to IL-1a were present in some patients with RA and serum titers tended to have a negative correlation with disease activity indices (45) . The autoantibody to IL-1a can be considered, in a sense, as a diseaseameliorating autoantibody. It is possible that such`autoantibody antagonism' re¯ects or is responsible for the stage of disease development or disease subtype. To address this point, it is necessary to analyze extensively the effects of autoantibodies to such defensive or offensive factors on the disease development in vivo by using animal models, and to investigate the relationship between the appearance of those autoantibodies and disease phenotypes. Interestingly, new therapies utilizing mAb to such disease-promoting factors as TNF-a, IL-6, IL-6 receptor, etc., in cases of RA have been shown to be bene®cial (46±48). This supports the idea that antibodies to causative factors can change the stage of disease.
Molecular mimicry is one hypothesis that explains the cause of autoantibody production (49, 50) . However, it has not yet been demonstrated by experiments. Nevertheless, to obtain a hint as to the origin of anti-FRP autoantibody production, we performed a homology search with the epitope sequence in FRP. Epitope analysis with the restricted set of antigen peptides disclosed that the sequence LKFVEQNE (residues 169±176) composed the epitope of FRP. The minimum number of amino acid residues in the liner epitope is generallỹ 15 (51) . Thus, the sequence LKFVEQNE may well be necessary but not suf®cient for immunoreactivity of FRP. The sequences homologous to LKFVEQNE were found in proteins from E. coli, Epstein±Barr virus, etc. It has been discussed that infection with various organisms including viruses, bacteria and mycoplasmas could be the trigger of disease development (52) . The induction of autoantibodies to FRP may be associated with some infection.
The present studies disclosed part of the function of FRP. FRP is an orphan molecule as yet and the signaling pathway of FRP is still unknown. Blocking effects on FRP activity by its antibodies suggest that FRP seems to have some cell surface receptor. It is probable that FRP can affect FOS/AP-1 target genes and regulate their products to exert their related activities. To clarify the de®nite function of FRP, its receptor should be identi®ed and its intracellular signal transduction should be elucidated.
In conclusion, in the pathophysiology of RA, FRP can be regarded as a preventive factor of joint matrix degradation and autoantibodies to FRP promote joint destruction by blocking FRP activity. It is not known to what extent the interaction of FRP and its autoantibodies modulates actual in¯ammation in joint spaces. However, FRP and its autoantibodies may provide some clues as to the process of disease development, and a new approach to the design of therapeutics in RA.
